

REMARKS

The Examiner has required that an election be made to one of the 10 groups of claims and has further required elections of one of the SEQ ID NOS. Applicant does not admit that each group of claims or each nucleotide sequence does not represent an independent and distinct invention. However, Applicant asserts that this election requirement is nevertheless burdensome to the applicant when considered in light of the relationship between the claimed nucleic acid sequences and limitations of the claims themselves. The Examiner has also requested an election of species regarding the cancers to be treated with the subject antibodies stating that the cancers have different etiologies and different effects.

Accordingly, applicant elects group V (Claim 21) for prosecution with traverse. Claims 1-20 and 22-41 have been canceled. Claim 21 has been amended to add claim language from the claims from which it depended. Applicant reserves the right to prosecute the non-elected/canceled claims in divisional or continuation applications.


Applicant also here with submits a corrected substitute sequence listing under 37 C.F.R. 1825. Also submitted are two copies of the replacement sequence listing on compact disk. Further, per the requirements, enclosed is a Statement stating that the compact disc and paper copy of the sequence listing are the same. It has come to applicant's attention that an error was introduced into SEQ ID NO:61. Residue 93 is currently incorrectly specified as Leu and should be Val. Residue 95 is currently incorrectly specified as His and should be Tyr. This correction is supported by the application as filed (in the originally filed Sequence Listing) and as such is not addition of new matter as the correct sequences for SEQ ID NO:61 is provided within the originally filed SEQ ID NO:25. In SEQ ID NO:25, residue 23(Glu) corresponds to residue 1 of SEQ ID NO:61. Residue 115 of SEQ ID NO:25, which corresponds to residue 93 of SEQ ID NO:61, is correctly indicated as Val. Residue 117 of SEQ ID NO:25, which corresponds to residue 95 of SEQ ID NO:61 is correctly indicated as TYR. Accordingly, applicant requests entry of the substitute sequence listing to correct this error. Thus, as corrected, SEQ ID NO:61 residue 93 should be Val and residue 95 should be Tyr.

CONCLUSION

Applicant respectfully requests entry of the present Response and consideration of the above-identified application on the merits. If the Examiner wishes to discuss the present application, the Examiner is respectfully invited to contact the undersigned.

Respectfully submitted,
KENYON & KENYON

Dated: September 3, 2004

By: 
Teresa A. Lavenue
Reg. No. 47,737

One Broadway
New York, NY 10004
Direct Dial: 202-220-4258
Fax: 202-220-4201